Malignant hyperthermia - what do we know in 2019?

Anaesthesiol Intensive Ther. 2019;51(3):169-177. doi: 10.5114/ait.2019.87646.

Authors

Agnieszka Cieniewicz¹, Janusz Trzebicki¹, Ewa Mayzner-Zawadzka², Anna Kostera-Pruszczyk³, Radosław Owczuk⁴

Affiliations

¹ 1st Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, Poland.
² Department of Anaesthesiology and Intensive Care, University of Warmia and Mazury in Olsztyn, Poland.
³ Department of Neurology, Warsaw Medical University, Poland.
⁴ Department of Anaesthesiology and Intensive Care, Medical University of Gdańsk, Poland.

PMID: 31493330
DOI: 10.5114/ait.2019.87646

No abstract available

Publication types

Review

MeSH terms

Anesthetics, Inhalation / administration & dosage
Anesthetics, Inhalation / adverse effects*
Humans
Malignant Hyperthermia / epidemiology
Malignant Hyperthermia / physiopathology*
Malignant Hyperthermia / therapy
Neuromuscular Depolarizing Agents / administration & dosage
Neuromuscular Depolarizing Agents / adverse effects*

Substances

Anesthetics, Inhalation
Neuromuscular Depolarizing Agents